Eleni C Papavasiliou
Overview
Explore the profile of Eleni C Papavasiliou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tselepis A, Hahalis G, Tellis C, Papavasiliou E, Mylona P, Kourakli A, et al.
J Lipid Res
. 2010 Jul;
51(11):3331-41.
PMID: 20625038
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an independent cardiovascular risk factor. We investigated the plasma levels of Lp-PLA(2) activity and mass as a function of plasma lipid levels, LDL subclass profile,...
2.
Rizos E, Spyrou A, Liberopoulos E, Papavasiliou E, Saougos V, Tselepis A, et al.
Open Cardiovasc Med J
. 2008 Oct;
1:22-6.
PMID: 18949087
The effect of the anti-hypertensive drug eprosartan on metabolic parameters is currently not extensively documented. We evaluated the effect of eprosartan on parameters involved in atherogenesis, oxidative stress and clotting...
3.
Lourida E, Georgiadis A, Papavasiliou E, Papathanasiou A, Drosos A, Tselepis A
Arthritis Res Ther
. 2007 Mar;
9(1):R19.
PMID: 17326817
Rheumatoid arthritis is a chronic inflammatory disease, associated with an excess of cardiovascular morbidity and mortality due to accelerated atherosclerosis. Oxidized low-density lipoprotein (oxLDL), the antibodies against oxLDL and the...
4.
Tentolouris N, Stylianou A, Lourida E, Perrea D, Kyriaki D, Papavasiliou E, et al.
J Lipid Res
. 2006 Oct;
48(1):218-25.
PMID: 17018886
Microalbuminuria (MA) is an independent risk factor for atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Postprandial lipemia is also associated with excess cardiovascular risk. However, the association between...
5.
Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD
Siamopoulos K, Gouva C, Katopodis K, Tzallas C, Nikolopoulos P, Papavasiliou E, et al.
Am J Kidney Dis
. 2006 Jul;
48(2):242-9.
PMID: 16860190
Background: Among lipid abnormalities observed in patients with chronic kidney disease (CKD) is a significant decrease in serum high-density lipoprotein cholesterol (HDL-C) levels. In a previously published randomized control trial,...
6.
Georgiadis A, Papavasiliou E, Lourida E, Alamanos Y, Kostara C, Tselepis A, et al.
Arthritis Res Ther
. 2006 May;
8(3):R82.
PMID: 16646989
We investigated lipid profiles and lipoprotein modification after immuno-intervention in patients with early rheumatoid arthritis (ERA). Fifty-eight patients with ERA who met the American College of Rheumatology (ACR) criteria were...
7.
Papavasiliou E, Gouva C, Siamopoulos K, Tselepis A
Nephrol Dial Transplant
. 2006 Jan;
21(5):1270-7.
PMID: 16421163
Background: Platelet activating factor acetylhydrolase (PAF-AH) is a Ca2+-independent phospholipase A2 that is secreted mainly from monocytes/macrophages. In human plasma, PAF-AH is associated primarily with low-density lipoprotein (LDL), while a...
8.
Papavasiliou E, Gouva C, Siamopoulos K, Tselepis A
Kidney Int
. 2005 Jun;
68(1):246-55.
PMID: 15954914
Background: Erythrocytes represent an important component of the antioxidant capacity of blood, comprising, in particular, intracellular enzymes, including platelet-activating factor acetylhydrolase (PAF-AH) and glutathione peroxidase (Gpx). We evaluated the erythrocyte...